Drug Information

Drug General Information
Drug ID
D0HB0V
Former ID
DNCL002524
Drug Name
JX-594
Synonyms
Pexastimogene devacirepvec
Indication Colorectal cancer; Liver cancer [ICD9: 153, 154, 140-229, 155, 203.0; ICD10:C18-C21, C22] Phase 2 [524578]
Company
Jennerex Biotherapeutics
Target and Pathway
Target(s) Granulocyte-macrophage colony-stimulating factor Target Info Modulator [528365]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
Natural killer cell mediated cytotoxicity
T cell receptor signaling pathway
Fc epsilon RI signaling pathway
TNF signaling pathway
Salmonella infection
Amoebiasis
HTLV-I infection
Transcriptional misregulation in cancer
Rheumatoid arthritis
NetPath Pathway IL1 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
TNFalpha Signaling Pathway
Pathway Interaction Database GMCSF-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Glucocorticoid receptor regulatory network
Alpha9 beta1 integrin signaling events
AP-1 transcription factor network
Calcium signaling in the CD4+ TCR pathway
Syndecan-2-mediated signaling events
Regulation of retinoblastoma protein
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways Cytokines and Inflammatory Response
Hematopoietic Stem Cell Differentiation
Interleukin-2 signaling
Interleukin-3, 5 and GM-CSF signaling
References
Ref 524578ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
Ref 528365Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.